Medtech & Services 2026: Fundamental Strength at Attractive Valuation
The medtech & services sector entered 2026 with robust fundamentals. Following a period of heightened volatility in 2025, the segment is currently trading at an attractive valuation level in historical terms, while earnings prospects remain stable.
By Marcel Fritsch, Head Healthcare Funds & Mandates, Bellevue Asset Management
Over the past year, the sector’s performance was driven less by operational setbacks than by a valuation adjustment. The expected price/earnings ratio currently stands at 22.5x, clearly below the historical average of 24.5x; before and after the pandemic, the sector traded at around 27x, corresponding to a discount of 9 percent and 20 percent, respectively.
At the same time, analysts’ earnings estimates for 2026 and 2027 have edged slightly higher. Many companies are reporting solid margins, stable order intake and well-filled product pipelines. The recent underperformance therefore primarily reflects a more cautious market valuation rather than a structural deterioration in fundamentals.
Historically, such phases have tended to be followed by a normalization of valuation multiples once new growth drivers became visible or market uncertainty receded.
Structural Growth with High Visibility
The investment case for the medtech segment remains fully intact. For high-quality companies in the sector, we expect mid- to high-single-digit organic revenue growth rates over the medium term, along with low double-digit earnings per share growth.
Specifically, we estimate the weighted average organic revenue growth of our medtech & services portfolio at +9.1 percent over the next five years, with earnings per share growth of +12.1 percent.
This development is driven by several long-term factors:
1. Aging populations, leading to higher treatment volumes
2. Rising prosperity and broader health insurance coverage in emerging markets
3. Innovation in diabetes, robotic-assisted surgery and structural heart disease. Artificial intelligence is a key innovation driver and supports product differentiation
In contrast to traditional pharmaceuticals, innovation cycles in medtech are often incremental. Products are continuously refined, regulatory risks are comparatively low (80–90 percent approval rate for FDA PMA approvals for complex products such as implants), and abrupt revenue losses due to patent expirations are rare. This structure provides high earnings visibility and sustainable cash flows.
Catalysts for 2026
Several potential catalysts are emerging for the current year. At the company level, significant product launches are expected in areas such as robotic-assisted surgery, structural heart therapies and electrophysiology. Numerous clinical data releases and new reimbursement policies should not only support revenue growth but also strengthen investor confidence. At the same time, M&A activity remains elevated: In 2026, transaction volume to date already amounts to USD 25 bn, following USD 46 bn for full-year 2025.
On the macro level, medtech companies are benefiting from slightly lower and more uniform tariffs following the US Supreme Court’s tariff decision. We expect only a marginal impact from the expiry of Obamacare-related subsidies. We anticipate that the new Federal Reserve Chair, Kevin Warsh, will pursue a more growth-oriented monetary policy from May 2026 onward, which should be supportive for growth-oriented medtech companies.
In addition, a sector rotation of capital is underway: After BioPharma has seen renewed capital inflows since the end of 2025, adjacent healthcare segments such as medtech have historically also benefited from this dynamic.
Positioning: Quality over Cyclicality
In this environment, a focus on companies with a clear innovation pipeline, sustainable competitive advantages and solid balance sheet structures appears particularly compelling. Market leaders with pricing power and recurring revenues are better positioned to absorb short-term market volatility.
The volatility of recent months was primarily valuation-driven. Fundamentally, many companies are now better capitalized and structurally more efficient than before the pandemic – while trading at more moderate valuation levels.
Conclusion
The medtech & services sector combines structural growth with a defensive demand profile. In our view, the recent valuation adjustment has improved the relative risk/return profile.
For long-term investors, this offers high-quality exposure to healthcare innovation – with clear visibility, solid cash flow generation and multiple identifiable catalysts for the coming quarters.
- Learn more about our investment solution here.
Bellevue – Excellence in Specialty Investments
Bellevue is a specialized asset manager listed on the SIX Swiss Exchange with core competencies covering healthcare strategies, entrepreneur strategies, alternative and traditional investment strategies. Established in 1993, Bellevue, a House of Investment Ideas staffed by 75 professionals, generates attractive investment returns and creates value added for clients and shareholders alike. Bellevue managed 5.3 bn francs in assets as of December 31, 2025.
Disclaimer: This document is neither directed to, nor intended for distribution or use by, any person or entity who is a citizen or resident of any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. The information and data presented in this document are not to be considered as an offer to buy or sell or an invitation to subscribe any securities or financial instruments. The information, opinions and estimates contained in this document reflect a judgment at the original date of release and are subject to change without notice. Liability for the accuracy or completeness of all information in this document is expressly disclaimed. This information does not take into account the specific or future investment objectives, the financial or tax situation or the particular needs of any specific recipient. This document does not constitute independent investment research. Interested investors should always seek professional advice before making an investment decision. The information in this document is provided without any guarantees or warranties, for information purposes only, and is intended only for the personal use of the recipient. Every investment involves some risk, especially with regard to fluctuations in value and return. Investments in foreign currency involve the additional risk that a foreign currency might lose value against an investor's reference currency. This document does not reflect all possible risk factors associated with an investment in the aforementioned securities or financial instruments. Historical performance data and financial market scenarios are no guarantee or indicator of current and future performance. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions. Commissions and costs adversely affect performance. Financial transactions should only be carried out after thorough study of the current prospectus and only on the basis of the most recently published prospectus and annual or semi-annual report. Bellevue Funds (Lux) SICAV is admitted for public distribution in Switzerland. Representative in Switzerland: Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, CH-1005 Lausanne. Paying agent in Switzerland: DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, P.O. Box, CH-8022 Zurich. Bellevue Funds (Lux) SICAV is admitted for public distribution in Austria. Paying and information agent: Zeidler Legal Process Outsourcing Limited, 19-22 Lower Baggot Street, Dublin 2, D02 X658, Ireland. The Bellevue Funds (Lux) SICAV is admitted for public distribution in Germany. Information agent: Zeidler Legal Process Outsourcing Limited, SouthPoint, Herbert House, Harmony Row, Grand Canal Dock, Dublin 2, Ireland. Bellevue Funds (Lux) SICAV is registered in the CNMV registry of foreign collective investment schemes distributed in Spain, under registration number 938. Representative: atl Capital, Calle de Montalbán 9, ES-28014 Madrid. Prospectus, Key Investor Information Document (PRIIP-KIID), the articles of association as well as the annual and semi-annual reports of the Bellevue Funds under Luxembourg law are available free of charge from the above-mentioned representative, paying, facilities and information agents as well as from Bellevue Asset Management AG, Theaterstrasse 12, CH-8001 Zurich. With respect to fund units distributed in or from Switzerland, the place of performance and jurisdiction is established at the registered office of the representative.
